title: Considerations when prescribing trimethoprim-sulfamethoxazole.
authors: Division of Clinical Pharmacology, Department of Medicine, University of Toronto, the Institute for Clinical Evaluative Sciences, Toronto, Ont. jmho2001@gmail.com
authors: Joanne M-W
authors: JM
authors: Ho
authors: David N
authors: DN
authors: Juurlink
mesh_terms: D000014:Abnormalities, Drug-Induced; D000890:Anti-Infective Agents / Q000009:adverse effects*; D000925:Anticoagulants / Q000009:adverse effects; D035843:Biomedical Research; D003577:Cytochrome P-450 Enzyme System / Q000187:drug effects; D003875:Drug Eruptions; D004347:Drug Interactions; D005260:Female; D005494:Folic Acid Deficiency / Q000139:chemically induced; D006402:Hematologic Diseases / Q000139:chemically induced; D006461:Hemolysis / Q000187:drug effects; D006801:Humans; D006947:Hyperkalemia / Q000139:chemically induced; D007003:Hypoglycemia / Q000139:chemically induced; D007004:Hypoglycemic Agents / Q000009:adverse effects; D016867:Immunocompromised Host; D007231:Infant, Newborn; D007236:Infant, Small for Gestational Age; D007668:Kidney / Q000187:drug effects; D009422:Nervous System Diseases / Q000139:chemically induced; D011247:Pregnancy; D015662:Trimethoprim, Sulfamethoxazole Drug Combination / Q000009:adverse effects*; D014859:Warfarin / Q000009:adverse effects
chemical_list: D000890:Anti-Infective Agents; D000925:Anticoagulants; D007004:Hypoglycemic Agents; D014859:Warfarin; D015662:Trimethoprim, Sulfamethoxazole Drug Combination; D003577:Cytochrome P-450 Enzyme System